You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 20, 2025

Patent: 6,896,886


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,896,886
Title: Use of botulinum toxins for treating various disorders and conditions and associated pain
Abstract:A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Inventor(s): Aoki; K. Roger (Laguna Hills, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Niguel, CA), Leon; Judith M. (Laguna Niguel, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:09/906,496
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 6,896,886

Introduction

United States Patent 6,896,886, hereafter referred to as the '886 patent, is a patent that has been granted by the United States Patent and Trademark Office (USPTO). To conduct a comprehensive and critical analysis of this patent, it is essential to understand the patent's claims, its position within the broader patent landscape, and the legal and procedural frameworks that govern it.

Understanding the Patent Claims

Claim Structure

The '886 patent consists of a set of claims that define the scope of the invention. These claims are typically categorized into independent and dependent claims. Independent claims stand alone and define the invention broadly, while dependent claims refer back to and further limit the independent claims[1].

Claim Analysis

To analyze the claims of the '886 patent, one must carefully read and interpret each claim. Here are some key steps:

  • Identify the Independent Claims: These claims are crucial as they set the broad boundaries of the invention.
  • Analyze Dependent Claims: These claims narrow down the invention and often add specific details or limitations.
  • Determine the Claim Scope: Understand what is covered and what is not covered by the claims.

Patent Landscape and Prior Art

Searching Prior Art

Before analyzing the '886 patent, it is important to search for prior art to understand the existing technological landscape. Tools like the USPTO's Patent Public Search, Global Dossier, and international databases such as those provided by the European Patent Office (EPO) and the World Intellectual Property Organization (WIPO) are invaluable for this purpose[1].

Identifying Related Patents

Using resources like the Common Citation Document (CCD) and the Patent Examination Data System (PEDS), one can identify related patents and understand how the '886 patent fits into the broader patent family[1].

Legal and Procedural Frameworks

The Leahy-Smith America Invents Act (AIA)

The AIA, enacted in 2011, significantly changed the U.S. patent system. It introduced new procedures such as inter partes review (IPR) and post-grant review (PGR), which allow for the challenge of patent validity at the Patent Trial and Appeal Board (PTAB)[2].

PTAB and Administrative Challenges

The PTAB, established under the AIA, provides a faster and less expensive alternative to federal court litigation for challenging patent validity. This can be particularly relevant for the '886 patent if it has been or could be challenged through IPR or PGR[2].

Challenges and Validity

Inter Partes Review (IPR) and Post-Grant Review (PGR)

If the '886 patent has been subject to IPR or PGR, it is crucial to review the PTAB's decisions. These proceedings can result in the cancellation of patent claims if the PTAB determines that the claims should not have been granted[2].

Criticisms of PTAB

Some critics argue that PTAB has made it too easy to challenge patents, creating uncertainty and potentially stifling innovation. Understanding these criticisms can provide context on the stability of the '886 patent's claims[2].

Patent Assertion Entities (PAEs)

Impact on Patent Litigation

PAEs, often referred to as "patent trolls," can significantly impact the patent landscape. If the '886 patent is held by a PAE, it may be subject to different assertion strategies, such as those employed by Litigation PAEs or Portfolio PAEs[3].

FTC Study on PAEs

The FTC study highlights that PAEs often focus on Information and Communication Technology (ICT) patents and can generate substantial revenue through licensing and litigation. This context is important if the '886 patent falls within these categories[3].

International Considerations

Global Patent System

The '886 patent may have counterparts or related applications in other countries. Using tools like Global Dossier and international patent databases, one can track the global status of the patent family[1].

Machine Translations and International Databases

Resources like esp@cenet from the EPO and PATENTSCOPE from WIPO provide access to international patent databases and machine translations, which can be crucial for understanding the global reach of the '886 patent[1].

Economic and Strategic Implications

Licensing and Revenue

Understanding the licensing strategies and revenue generated from the '886 patent can provide insights into its economic significance. Portfolio PAEs, for example, often negotiate licenses covering large portfolios, which can be highly lucrative[3].

Litigation Trends

The recent upswing in US patent litigation, including the increase in NPE filings and PTAB petitions, indicates a dynamic and potentially challenging environment for patent holders. The '886 patent's position within this landscape could affect its value and enforceability[5].

Key Takeaways

  • Claims Analysis: Carefully review the independent and dependent claims to understand the scope of the invention.
  • Prior Art and Patent Landscape: Use comprehensive search tools to identify related patents and prior art.
  • Legal Frameworks: Consider the impact of AIA procedures like IPR and PGR on the patent's validity.
  • PAEs and Litigation: Understand the role of PAEs and their strategies in patent assertion.
  • International Considerations: Track the global status of the patent family and use international databases.

FAQs

What is the significance of the Leahy-Smith America Invents Act (AIA) in patent law?

The AIA is a significant patent statute that introduced new procedures like inter partes review (IPR) and post-grant review (PGR), providing a faster and less expensive way to challenge patent validity compared to federal court litigation[2].

How do Patent Assertion Entities (PAEs) impact patent litigation?

PAEs can significantly impact patent litigation by asserting patents aggressively, often without manufacturing or selling the patented products. They generate revenue through licensing and litigation, and their activities can be categorized into Portfolio PAEs and Litigation PAEs[3].

What tools are available for searching prior art and related patents?

Tools such as the USPTO's Patent Public Search, Global Dossier, Common Citation Document (CCD), and international databases like esp@cenet and PATENTSCOPE are essential for searching prior art and related patents[1].

How does the PTAB affect the validity of patents like the '886 patent?

The PTAB can affect the validity of patents through IPR and PGR proceedings. If a patent is challenged and the PTAB determines that the claims should not have been granted, the patent claims can be cancelled[2].

What are the economic implications of patent litigation trends for the '886 patent?

The recent increase in patent litigation and PTAB petitions indicates a challenging environment for patent holders. This could affect the value and enforceability of the '886 patent, especially if it is subject to licensing or litigation strategies employed by PAEs[5].

Sources

  1. USPTO - Search for Patents: https://www.uspto.gov/patents/search
  2. Congressional Research Service - The Patent Trial and Appeal Board and Inter Partes Review: https://crsreports.congress.gov/product/pdf/R/R48016
  3. FTC - Patent Assertion Entity Activity: An FTC Study: https://www.ftc.gov/system/files/documents/reports/patent-assertion-entity-activity-ftc-study/p131203_patent_assertion_entity_activity_an_ftc_study_0.pdf
  4. U.S. Department of Commerce - U.S. Patent and Trademark Office: https://www.commerce.gov/bureaus-and-offices/uspto
  5. RPX Corporation - Q3 in Review: US NPE Upswing Continues as UPC Comes Further into Focus: https://www.rpxcorp.com/blog_post/q3-in-review-us-npe-upswing-continues-as-upc-comes-further-into-focus/

More… ↓

⤷  Try for Free

Details for Patent 6,896,886

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 December 09, 1991 ⤷  Try for Free 2013-12-28
Abbvie Inc. BOTOX onabotulinumtoxina For Injection 103000 December 09, 1991 ⤷  Try for Free 2013-12-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.